Abstract
Objectives:
To review novel targeted therapies for the treatment of leukemia.
Data sources:
Professional journals, books, and government publications.
Conclusion:
Nonspecific cytotoxic chemotherapeutic agents provide marginal therapeutic benefit and significant toxicity when used in the treatment of leukemia. There is a tremendous need for new therapies with increased efficacy and decreased adverse effects. Advances in molecular science, genetics, and immunology, along with improved laboratory technology, have led to the discovery of unique targets integral to the growth and proliferation of malignant cells which are providing the foundation for the development of a new generation of antitumor agents.
Implications for nursing practice:
Nurses must be prepared to educate patients, administer novel therapies, and manage side effects.
MeSH terms
-
Alemtuzumab
-
Aminoglycosides*
-
Anti-Bacterial Agents / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Arsenic Trioxide
-
Arsenicals / therapeutic use
-
Benzamides
-
Dose-Response Relationship, Drug
-
Drug Interactions
-
Gemtuzumab
-
Humans
-
Imatinib Mesylate
-
Leukemia / drug therapy*
-
Leukemia / nursing*
-
Nurse's Role*
-
Nurse-Patient Relations
-
Oncology Nursing / methods*
-
Oncology Nursing / standards*
-
Oxides / therapeutic use
-
Patient Education as Topic
-
Piperazines / therapeutic use
-
Prognosis
-
Pyrimidines / therapeutic use
-
Randomized Controlled Trials as Topic
-
Tretinoin / therapeutic use
Substances
-
Aminoglycosides
-
Anti-Bacterial Agents
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Antineoplastic Agents
-
Arsenicals
-
Benzamides
-
Oxides
-
Piperazines
-
Pyrimidines
-
Alemtuzumab
-
Tretinoin
-
Imatinib Mesylate
-
Gemtuzumab
-
Arsenic Trioxide